35:I[703058,["/_next/static/immutable/chunks/355lxm8rh3fxr.js","/_next/static/immutable/chunks/0yecwcl2vsgzm.js","/_next/static/immutable/chunks/33s6yl_7t575t.js","/_next/static/immutable/chunks/2sgwc-d-l730j.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/34zte87e1oxbr.js","/_next/static/immutable/chunks/3o8_7x7kr1gqd.js","/_next/static/immutable/chunks/3gndzt6n9hhhz.js","/_next/static/immutable/chunks/368brjxhfaune.js","/_next/static/immutable/chunks/2-7hs63mi7grl.js","/_next/static/immutable/chunks/1xa6orki-joi9.js","/_next/static/immutable/chunks/316o2u2mp21uq.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/0g9dls0-elfj5.js"],"PaperListPageClient"] 36:T4f2,A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P < .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P < .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P < .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P < .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09).37:Tb79,Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear. To evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group. This retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024. Prevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors. A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P < .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P < .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P < .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P < .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09). In this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.38:Tea2,ImportanceAutoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear.ObjectiveTo evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group.Design, Setting, and ParticipantsThis retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024.Main Outcomes and MeasuresPrevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors.ResultsA total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P &lt; .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P &lt; .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P &lt; .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P &lt; .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09).Conclusions and RelevanceIn this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.22:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Atherosclerotic Cardiovascular Disease in Dermatology: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed Dermatology papers on Atherosclerotic Cardiovascular Disease (condition). Clinician-written summaries and practical action steps. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/Dermatology/condition/Atherosclerotic%20Cardiovascular%20Disease\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Dermatology\",\"item\":\"https://www.reachrx.ai/hub/Dermatology\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Atherosclerotic Cardiovascular Disease\",\"item\":\"https://www.reachrx.ai/hub/Dermatology/condition/Atherosclerotic%20Cardiovascular%20Disease\"}]}}"}}]],["$","$L35",null,{"title":"Atherosclerotic Cardiovascular Disease in Dermatology: Research & Clinical Takeaways","description":"Discover peer-reviewed Dermatology research on Atherosclerotic Cardiovascular Disease with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamadermatol.2024.4991","pmid":"39630434","title":"Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-12-04T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.4991","source_score":145,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-02-22","doi":"10.1001/jamadermatol.2024.4991","days":"30","issn":"2168-6068","rank":"1","field":"Clinical Medicine","score":"145","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.4991","title":"Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus.","journal":"JAMA dermatology","methods":"","results":"$36","abstract":"$37","keywords":[],"pubmed_id":"39630434","conclusions":"","publication_date":"2024-12-04T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.4991","URL":"https://doi.org/10.1001/jamadermatol.2024.4991","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2826498/jamadermatology_chen_2024_oi_240057_1739305465.32005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"175","type":"journal-article","issue":"2","score":1,"title":["Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus"],"author":[{"given":"Henry W.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}]},{"given":"Jialiang","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Quantitative Biomedical Research Center, Peter O’Donnell Jr School of Public Health, Dallas"}]},{"given":"Donghan M.","family":"Yang","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Quantitative Biomedical Research Center, Peter O’Donnell Jr School of Public Health, Dallas"}]},{"given":"Yang","family":"Xie","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Quantitative Biomedical Research Center, Peter O’Donnell Jr School of Public Health, Dallas"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas"}]},{"given":"Benjamin F.","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}]}],"issued":{"date-parts":[[2025,2,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2024-12-04T16:01:05Z","timestamp":1733328065000,"date-parts":[[2024,12,4]]},"indexed":{"date-time":"2025-05-27T13:32:20Z","timestamp":1748352740115,"date-parts":[[2025,5,27]]},"subject":[],"abstract":"$38","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2826498"}},"subtitle":[],"deposited":{"date-time":"2025-02-19T16:01:39Z","timestamp":1739980899000,"date-parts":[[2025,2,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,2,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaut.2018.11.001","key":"doi240057r1","year":"2019","issue":null,"author":"Fava","volume":"96","first-page":"1","unstructured":null,"article-title":"Systemic lupus erythematosus: diagnosis and clinical management.","journal-title":"J Autoimmun","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40265-013-0173-5","key":"doi240057r2","year":"2014","issue":"2","author":"Churton","volume":"74","first-page":"169","unstructured":null,"article-title":"Does treatment of psoriasis reduce the risk of cardiovascular disease?","journal-title":"Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12016-016-8560-9","key":"doi240057r3","year":"2016","issue":"2","author":"Yang","volume":"51","first-page":"240","unstructured":null,"article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis.","journal-title":"Clin Rev Allergy Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.24537","key":"doi240057r4","year":"2009","issue":"10","author":"Hak","volume":"61","first-page":"1396","unstructured":null,"article-title":"Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study.","journal-title":"Arthritis Rheum","doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.23018","key":"doi240057r5","year":"2017","issue":"6","author":"Aviña-Zubieta","volume":"69","first-page":"849","unstructured":null,"article-title":"Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study.","journal-title":"Arthritis Care Res (Hoboken)","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0190-9622(81)80261-7","key":"doi240057r6","year":"1981","issue":"4","author":"Gilliam","volume":"4","first-page":"471","unstructured":null,"article-title":"Distinctive cutaneous subsets in the spectrum of lupus erythematosus.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1155/2017/3972706","key":"doi240057r7","year":"2017","issue":null,"author":"Akarsu","volume":"2017","first-page":null,"unstructured":null,"article-title":"High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study.","journal-title":"J Immunol Res","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12933-020-01166-6","key":"doi240057r8","year":"2020","issue":"1","author":"Guembe","volume":"19","first-page":"195","unstructured":null,"article-title":"Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort.","journal-title":"Cardiovasc Diabetol","doi-asserted-by":"publisher"},{"DOI":"10.1177/0961203321990106","key":"doi240057r9","year":"2021","issue":"5","author":"Westermann","volume":"30","first-page":"752","unstructured":null,"article-title":"Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2011.10773.x","key":"doi240057r10","year":"2012","issue":"5","author":"Grönhagen","volume":"166","first-page":"1053","unstructured":null,"article-title":"Increased risk of cancer among 3663 patients with cutaneous lupus erythematosus: a Swedish nationwide cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1177/09612033231154785","key":"doi240057r11","year":"2023","issue":"4","author":"Chen","volume":"32","first-page":"580","unstructured":null,"article-title":"Older black race is a risk factor for metabolic syndrome in cutaneous lupus erythematosus.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1177/0961203317716306","key":"doi240057r12","year":"2017","issue":"13","author":"Ahlehoff","volume":"26","first-page":"1435","unstructured":null,"article-title":"Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: a Danish nationwide cohort study.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1177/0961203316651739","key":"doi240057r13","year":"2017","issue":"1","author":"Hesselvig","volume":"26","first-page":"48","unstructured":null,"article-title":"Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1186/1471-2377-12-41","key":"doi240057r14","year":"2012","issue":null,"author":"Zöller","volume":"12","first-page":"41","unstructured":null,"article-title":"Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden.","journal-title":"BMC Neurol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0033442","key":"doi240057r15","year":"2012","issue":"3","author":"Zöller","volume":"7","first-page":null,"unstructured":null,"article-title":"Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-022-06302-z","key":"doi240057r16","year":"2022","issue":"11","author":"Shams-Eldin","volume":"41","first-page":"3525","unstructured":null,"article-title":"Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.","journal-title":"Clin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ebiom.2023.104639","key":"doi240057r17","year":"2023","issue":null,"author":"Olbrich","volume":"93","first-page":null,"unstructured":null,"article-title":"Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.","journal-title":"EBioMedicine","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(07)61602-X","key":"doi240057r19","year":"2007","issue":"9596","author":"von Elm","volume":"370","first-page":"1453","unstructured":null,"article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pmed.1001885","key":"doi240057r20","year":"2015","issue":"10","author":"Benchimol","volume":"12","first-page":null,"unstructured":null,"article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.","journal-title":"PLoS Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.vaccine.2013.06.104","key":"doi240057r22","year":"2013","issue":null,"author":"Moores","volume":"31","first-page":"K62","unstructured":null,"article-title":"A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data.","journal-title":"Vaccine","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.3447","key":"doi240057r23","year":"2013","issue":"8","author":"Asgari","volume":"22","first-page":"842","unstructured":null,"article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20597","key":"doi240057r24","year":"2021","issue":"6","author":"O’Kane","volume":"185","first-page":"1112","unstructured":null,"article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamacardio.2022.3839","key":"doi240057r26","year":"2023","issue":"1","author":"Nanna","volume":"8","first-page":"89","unstructured":null,"article-title":"Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice.","journal-title":"JAMA Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.14.1735","key":"doi240057r28","year":"2006","issue":"14","author":"Gelfand","volume":"296","first-page":"1735","unstructured":null,"article-title":"Risk of myocardial infarction in patients with psoriasis.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.09941.x","key":"doi240057r29","year":"2010","issue":"3","author":"Abuabara","volume":"163","first-page":"586","unstructured":null,"article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.22892","key":"doi240057r30","year":"2016","issue":"11","author":"Singh","volume":"68","first-page":"1664","unstructured":null,"article-title":"Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study.","journal-title":"Arthritis Care Res (Hoboken)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijwd.2021.08.015","key":"doi240057r31","year":"2021","issue":null,"author":"Keyes","volume":"7","first-page":"560","unstructured":null,"article-title":"Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.","journal-title":"Int J Womens Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.05.023","key":"doi240057r32","year":"2015","issue":"2","author":"Chasset","volume":"73","first-page":null,"unstructured":null,"article-title":"Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.12.025","key":"doi240057r33","year":"2015","issue":"4","author":"Chasset","volume":"72","first-page":"634","unstructured":null,"article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2009.199","key":"doi240057r34","year":"2009","issue":"9","author":"Boeckler","volume":"145","first-page":"1012","unstructured":null,"article-title":"Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.13006","key":"doi240057r35","year":"2014","issue":"3","author":"Kuhn","volume":"171","first-page":"571","unstructured":null,"article-title":"Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jval.2017.09.002","key":"doi240057r36","year":"2018","issue":"3","author":"Huo","volume":"21","first-page":"334","unstructured":null,"article-title":"Sensitivity of claims-based algorithms to ascertain smoking status more than doubled with meaningful use.","journal-title":"Value Health","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-020-05257-3","key":"doi240057r37","year":"2021","issue":"2","author":"Guo","volume":"40","first-page":"491","unstructured":null,"article-title":"Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.","journal-title":"Clin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jacc.2018.11.003","key":"doi240057r38","year":"2019","issue":"24","author":"Grundy","volume":"73","first-page":"e285","unstructured":null,"article-title":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.","journal-title":"J Am Coll Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19800","key":"doi240057r39","year":"2021","issue":"3","author":"Zhu","volume":"185","first-page":"563","unstructured":null,"article-title":"Modular gene analysis reveals distinct molecular signatures for subsets of patients with cutaneous lupus erythematosus.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.1600108","key":"doi240057r40","year":"2017","issue":"6","author":"Buie","volume":"199","first-page":"1979","unstructured":null,"article-title":"IFN-a negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus.","journal-title":"J Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.30165","key":"doi240057r41","year":"2011","issue":"2","author":"Li","volume":"63","first-page":"492","unstructured":null,"article-title":"Interferon-a priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-a and atherosclerosis in lupus.","journal-title":"Arthritis Rheum","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamahealthforum.2022.1812","key":"doi240057r42","year":"2022","issue":"7","author":"Nead","volume":"3","first-page":null,"unstructured":null,"article-title":"Cautions when using race and ethnicity in administrative claims data sets.","journal-title":"JAMA Health Forum","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjsurg.2023.05.011","key":"doi240057r43","year":"2023","issue":"4","author":"Johnson","volume":"226","first-page":"463","unstructured":null,"article-title":"The accuracy of race & ethnicity data in US based healthcare databases: a systematic review.","journal-title":"Am J Surg","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240057r18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"IBM. MarketScan Research. Accessed March 20, 2022. https://www.ibm.com/watson/health/resources/ipv-opv/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1177/12034754241301405","key":"doi240057r21","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Guo? L, Said? J, Nambudiri? V, Merola? J. Development and validation of algorithms to identify cutaneous lupus patients using diagnostic codes and prescription data. American College of Rheumatology. 2022. Accessed October 30, 2024. https://acrabstracts.org/abstract/development-and-validation-of-algorithms-to-identify-cutaneous-lupus-patients-using-diagnostic-codes-and-prescription-data/","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"doi240057r25","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ccoptimalmatch: Implementation of case-control optimal matching. 2021. Accessed October 30, 2024. https://cran.r-project.org/web/packages/ccoptimalmatch/index.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240057r27","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2019. Accessed October 30, 2024. https://www.R-project.org/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,2,1]]},"reference-count":43,"published-online":null,"references-count":43,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2024.4991","is_oa":false,"title":"Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus","updated":"2025-05-22T18:42:22+00:00","published_date":"2024-12-04","best_oa_location":null}},"created_at":"2025-09-19T22:42:41.309Z","updated_at":"2025-09-19T22:54:29.411Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"condition","value":"Atherosclerotic Cardiovascular Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"condition","value":"Cutaneous Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"condition","value":"Systemic Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"sample_size","value":"n=306,770","value_numeric":306770},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"warning","value":"Controls were matched 10:1 to the CLE group; matching details for comparisons with SLE and psoriasis are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"warning","value":"Design is a retrospective matched cohort using claims data; classification as a retrospective cohort is approximate.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4991","tag_type":"warning","value":"Incident ASCVD was defined using hospitalization events only, which can underestimate total events.","value_numeric":null}],"summaries":{"what_studied":"A retrospective matched longitudinal cohort (IBM MarketScan, 2018-2020) compared ASCVD prevalence and incidence in CLE (n=8,138), SLE (n=24,675), and psoriasis (n=192,577) versus matched controls (n=81,380) over up to 3 years, using multivariable logistic and Cox models adjusted for age, sex, and cardiovascular risk factors.","key_result":"Prevalent ASCVD odds were higher than controls for CLE (OR 1.72, 95% CI 1.45-2.02) and SLE (OR 2.41, 95% CI 2.14-2.70), but not for psoriasis (OR 1.03, 95% CI 0.95-1.11). Over a median 3 years, ASCVD incidence per 1000 person-years was SLE 24.8, CLE 15.2, psoriasis 14.0, and controls 10.3; adjusted HRs vs controls were SLE 2.23 (95% CI 2.05-2.43), CLE 1.32 (95% CI 1.13-1.55), and psoriasis 1.06 (95% CI 0.99-1.13).","limitations":"Incident ASCVD was captured through hospitalization events only, which may miss nonhospitalized events. Potential residual confounding from unmeasured factors (e.g., smoking) remains. Findings are from a commercially insured claims database, which may limit generalizability.","practice_takeaway":"Patients with CLE appear to have increased ASCVD risk; consider cardiovascular risk screening similar to other higher-risk groups."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"category","value":"Dermatology"},{"tag_type":"condition","value":"Atherosclerotic Cardiovascular Disease"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Dermatology","href":"/hub/Dermatology"},{"name":"Atherosclerotic Cardiovascular Disease"}],"hrefConfig":{"basePath":"/hub/Dermatology/papers","webViewQueryParams":{"hub_ctx":"category_tag","hub_category":"Dermatology","hub_tag_type":"condition","hub_tag_value":"Atherosclerotic Cardiovascular Disease"}}}]]

Papers

Papers